Bone Marrow–Derived Mesenchymal Stem Cells Enhance Bacterial Clearance and Preserve Bioprosthetic Integrity in a Model of Mesh Infection

Erik T. Criman, MD*
Wendy E. Kurata, MS†
Karen W. Matsumoto, BS†
Harry T. Aubin, MD*
Carmen E. Campbell, MS†
Lisa M. Pierce, DSc†

Background: The reported incidence of mesh infection in contaminated operative fields is as high as 30% regardless of the material used. Recently, mesenchymal stem cells (MSCs) have been shown to possess favorable immunomodulatory properties and improve tissue incorporation when seeded onto bioprosthetics. The aim of this study was to evaluate whether seeding noncrosslinked bovine pericardium (Veritas Collagen Matrix) with allogeneic bone marrow–derived MSCs improves infection resistance in vivo after inoculation with Escherichia coli (E. coli).

Methods: Rat bone marrow–derived MSCs at passage 3 were seeded onto bovine pericardium and cultured for 7 days before implantation. Additional rats (n = 24) were implanted subcutaneously with MSC-seeded or unseeded mesh and inoculated with $7 \times 10^5$ colony-forming units of E. coli or saline before wound closure (group 1, unseeded mesh/saline; group 2, unseeded mesh/E. coli; group 3, MSC-seeded mesh/E. coli; 8 rats per group). Meshes were explanted at 4 weeks and underwent microbiologic and histologic analyses.

Results: MSC-seeded meshes inoculated with E. coli demonstrated superior bacterial clearance and preservation of mesh integrity compared with E. coli–inoculated unseeded meshes (87.5% versus 0% clearance; $p = 0.001$). Complete mesh degradation concurrent with abscess formation was observed in 100% of rats in the unseeded/E. coli group, which is in contrast to 12.5% of rats in the MSC-seeded/E. coli group. Histologic evaluation determined that remodeling characteristics of E. coli–inoculated MSC-seeded meshes were similar to those of uninfected meshes 4 weeks after implantation.

Conclusions: Augmenting a bioprosthetic material with stem cells seems to markedly enhance resistance to bacterial infection in vivo and preserve mesh integrity.

(Plast Reconstr Surg Glob Open 2016;4:e751; doi: 10.1097/GOX.0000000000000765; Published online 17 June 2016.)

Mesh has been used for decades in the diverse field of reconstructive surgery. Despite advances in the development of synthetic and bioprosthetic materials and improvements in surgical techniques, mesh infection remains a challenging and costly complication, particularly in abdominal wall reconstruction. Although mesh placement has reduced the incidence of ventral hernia recurrence by 50% over suture repair alone, published rates of infection after this procedure range from 4% to 16%. Infection has been reported in as many as 30% of cases after mesh use in contaminated operative fields regardless of the material used. In addition, infection is known to be an independent risk factor for hernia recurrence, and with each procedure, both cost and recurrence risk increase. An estimated 250,000 ven-
ternal hernia repairs are performed annually in the United States alone, and mesh usage is expected to rise with emerging evidence supporting prophylactic insertion during the index operation.

Implanted bioprosthetic and synthetic materials are thought to resist infection by facilitating neovascularization and host tissue incorporation subsequent to an inflammatory response elicited by the collective trauma of surgery and the presence of a foreign body. To the extent that the scaffold is able to become populated by host cells, it is able to resist and even clear infection. Introduction of an acellular substrate into a surgical wound, however, creates dependence on the host to effect cellular infiltration and immunologic sterilization. This reliance may be problematic in patient populations known to have impediments to wound healing (e.g., because of poorly controlled diabetes, smoking, malnutrition, steroid use, renal failure, and irradiation), especially in the setting of bacterial contamination.

Recently, mesenchymal stem cells (MSCs) seeded onto the surface of bioprosthetics have been found to enhance mesh incorporation into surrounding host tissue, increase neovascularization, and improve mechanical properties of meshes. MSCs have been shown to benefit wound healing not only by promoting tissue regeneration and increasing the recruitment of macrophages and endothelial cells into the wound but also by possessing immunomodulatory and antimicrobial activities. Animal studies have determined that the administration of MSCs in a variety of in vivo conditions augments antibacterial responses against both Gram-negative and Gram-positive pathogens, decreases inflammation, and leads to faster bacterial clearance.

To date, no published studies have addressed whether seeding mesh materials with MSCs improves the host response to bacterial contamination of implanted materials. The objective of this study was, therefore, to determine whether seeding a commercially available bioprosthetic with allogeneic bone marrow–derived MSCs improves infection resistance in vivo after inoculation with a common Gram-negative pathogen.

MATERIALS AND METHODS

Animals

A total of 26 male Sprague-Dawley rats weighing approximately 350 g were used. Animals were obtained from Taconic (Germantown, N.Y.) and housed in the Tripler Army Medical Center animal facility. The study protocol was approved by the Institutional Animal Care and Use Committee at the Tripler Army Medical Center. Investigators complied with the policies as prescribed in the US Department of Agriculture Animal Welfare Act and the National Research Council’s Guide for the Care and Use of Laboratory Animals. Facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Study Design

An established rat infection model was used to evaluate whether seeding acellular, noncrosslinked bovine pericardium (Veritas Collagen Matrix, Synovis Life Technologies Inc., St. Paul, Minn.) with MSCs improves resistance to bacterial contamination after inoculation with Escherichia coli (E. coli). Twenty-four rats underwent subcutaneous implantation in the dorsum with two 3.75-cm pieces of mesh. Rats were assigned randomly to 1 of the 3 groups, with 8 rats per group. Group 1 was implanted with unseeded mesh and received 200 μL of sterile saline into the surgical wound after mesh placement but before skin closure. Group 2 was implanted with unseeded mesh and received 200 μL of bacterial suspension containing 7×10⁵ colony-forming units (cfu) E. coli to simulate a contaminated surgical field. Group 3 was implanted with allogeneic rat bone marrow–derived MSC-seeded mesh and received 200 μL of bacterial suspension containing 7×10⁵ cfu E. coli. Veritas Collagen Matrix was selected because its use is described for the reconstruction of complex abdominal wall defects. Four weeks after surgery, explants underwent microbiologic and histologic analyses. This time point was chosen because we wished to examine a period during which meshes should be actively remodeling and acute surgical wounds should have healed.

Isolation of Rat Bone Marrow–Derived MSCs and Preparation of MSC-Seeded Mesh

After lethal intraperitoneal injection of a pentobarbital-based euthanasia solution, bone marrow from 2 additional rats was mechanically harvested by flushing femurs and tibias with Medium 199 (M199E, Sigma Aldrich, St. Louis, Mo.) using a 22-gauge needle and 3-mL syringe under aseptic conditions. The pooled cell suspension was passed through a 40-μm strainer, centrifuged at 200 g for 5 minutes, resuspended in 25 mL of cell culture medium (MesenCult Proliferation Kit with MesenPure, STEMCELL Technologies Inc., Vancouver, British Columbia, Canada), and cultured on two 75-cm² tissue culture flasks at 37°C and 5% CO₂. MSCs were expanded in vitro in a complete medium (M199E/10% fetal bovine serum [MSC-qualified fetal bovine serum, Life Technologies Corp., Grand Island, N.Y.]/1× penicillin–streptomycin). To demonstrate the multipotency of expanded cells used for seeding, aliquots of MSCs at passage 3 were successfully differentiated into adipocytes and osteoblasts using MesenCult adipogenic and osteogenic differentiation media from STEMCELL Technologies Inc. according to the manufacturer’s instructions (not shown).

Seven days before implantation, Veritas Collagen Matrix was cut into 2.5×1.5 cm strips using an aseptic technique. Meshes were presoaked in MSC-qualified FBS for approximately 1 hour to facilitate cell adhesion and then placed into 6-well culture plates (1 mesh per well) containing a complete medium. Using a pipette, 7.5×10⁵ MSCs at passage 3 were dripseeded onto each mesh (equivalent to 2×10⁶ MSCs per cm²), and plates were incubated at 37°C and 5% CO₂. On day 3, meshes were flipped over and seeded with an additional 7.5×10⁵ MSCs, yielding a total of 1.5×10⁶ MSCs per mesh (4×10⁷ MSCs per cm²). This number of cells is consistent with seeded cell densities used in previous studies. Cells were given a fresh medium every 2 to 3 days and were implanted in
rats after 7 days in culture. This incubation period is consistent with preimplantation seeding protocols advanced by others. On the day of surgery, excellent cell viability (>95% estimated semiquantitatively) and adherence were visualized on 4 meshes (not implanted in rats) using an Olympus IX71 fluorescent microscope (Olympus America Inc., Center Valley, Pa.) as determined by a LIVE/DEAD cell viability assay (Life Technologies Corp.) following the manufacturer’s instructions (Fig. 1). Before evaluation, samples were moved to a new 6-well plate to ensure that visualized cells were adherent to meshes and not to the bottom of wells.

Bacterial Inoculum Preparation

*E. coli* was chosen as the contaminant for this study given its clinical relevance as a common enteric organism and based on previous work in our laboratory, demonstrating profound mesh degradation and clinically apparent abscess formation after *E. coli* colonization on noncrosslinked porcine dermis. *E. coli* (ATCC #25922) was obtained from American Type Culture Collection (Manassas, Va.). Two days before surgery, an aliquot was thawed from frozen stock and cultured on blood agar plates for 48 hours with a minimum of 1 passage between plates. Culture concentration was determined by spectrophotometry (optical density,OD$_{600}$) and compared with a predetermined growth curve. Cultures were brought to the desired concentration in 0.9% sterile saline and verified by plating serial 10-fold dilutions (in triplicate) of the final solution used during surgery.

Surgery and Tissue Collection

Surgery, anesthesia, and analgesia were performed as described previously. Briefly, bilateral 3-cm dorsal incisions were made 1 cm lateral to the spine. A subcutaneous pocket was created at each incision site, and 1 piece of mesh (of the same type and inoculum) was placed into each pocket. The bacterial inoculum (200 μL suspension of $7 \times 10^5$ cfu *E. coli*) or sterile saline (200 μL) was pipetted onto each implanted mesh before skin closure with sterile stainless steel clips (Braintree Scientific, Braintree, Mass.).

---

**Fig. 1.** Veritas Collagen Matrix seeded with rat bone marrow–derived MSCs. MSCs at passage 3 in culture (A), MSC-seeded meshes on day 6 after seeding $7.5 \times 10^5$ cells per side (equivalent to $2 \times 10^5$ MSCs per cm$^2$ per side) (B), and representative images of a LIVE/DEAD cell viability assay performed on MSC-seeded mesh after 7 days in culture stained with calcein to view live cells (green; C) and ethidium to view dead cells (red; D). Note the high cell viability and density on mesh at 7 days.
Animals were evaluated daily for signs of local infection, sepsis, pain or distress, or wound complications. On postoperative day 28, rats were deeply anesthetized using a combination of ketamine (75 mg/kg) and dexmedetomidine (250 µg/kg) administered intraperitoneally, and cardiac puncture was performed to determine bloodstream infection rates as described. Rats were killed by intracardiac injection of a pentobarbital-based euthanasia solution, and meshes were carefully excised under sterile conditions. In the event that the mesh could not be readily identified, the subcutaneous space was explored from the dorsal midline to the anterior axillary line to rule out migration and to confirm complete degradation. The length and width of each explanted mesh were measured to evaluate contraction (decrease in surface area) of the implant. One strip of mesh from each animal was divided into 2 equal pieces for bacterial recovery and histologic analyses. The second implant (if present) was stored at −80°C for future biomechanical testing.

**Bacterial Recovery at Explant**

Explanted meshes were submerged in 1 mL 0.9% sterile saline and vortexed for 1 minute to dissociate adherent bacteria as described. Serial 10-fold dilutions were plated in triplicate on blood agar and incubated at 37°C for 24 hours before counting colonies. Gram stains were performed, and meshes were scored as positive if the clinical isolates were Gram negative. Bacterial clearance was defined as the number of animals with sterile cultures divided by the total number of inoculated animals and expressed as a percentage.

**Histology**

Samples were fixed in formalin and embedded in paraffin, and 5-µm sections were stained with hematoxylin and eosin. Specimens were evaluated by 2 blinded investigators at 40× to 200× magnification. They were graded for cellular infiltration, cell types present, extracellular matrix deposition, scaffold degradation, fibrous encapsulation, and neovascularization according to a scale used by Jenkins et al and used previously by our laboratory. Higher scores on this scale represent more favorable implant remodeling characteristics. A composite histologic score was also calculated for each sample by taking the average of each of the scores in each of the subcategories.

**Statistical Analysis**

All results were reported as mean ± SEM. The Kruskal–Wallis 1-way analysis of variance on ranks was used to determine weight differences among the 3 experimental groups followed by pairwise multiple comparisons using the Dunn’s method to identify specific differences between groups. Comparisons between 2 groups were performed using the t test or nonparametric Mann–Whitney rank sum test if indicated. Proportions pertaining to bacterial clearance, wound complications, and biologic mesh degradation comparisons were performed using the Fisher exact test. Statistical analyses were performed using SigmaPlot 11.2 software (Systat Software Inc., San Jose, Calif.) with a p value less than 0.05 considered significant.

---

**RESULTS**

**Postoperative Course**

All animals survived the 4-week postoperative period. During the first week, 1 rat in the *E. coli*/unseeded mesh group had reduced eating habits and activity level compared with other rats in this group likely because of complications from anesthesia, and therefore, this animal was conservatively removed from weight analyses to prevent confounding. Because activity and weight returned to normal during the second half of the study period, this animal was used in all subsequent analyses. Significant differences were noted in weight gain among the 3 groups during the first 2 postoperative weeks (p < 0.002, week 1; p < 0.007, week 2; Fig. 2). Rats implanted with *E. coli*/unseeded mesh demonstrated reduced weight gain (p < 0.05) relative to the other 2 groups 1 week after surgery. At week 2, both *E. coli* groups demonstrated reduced weight gain (p < 0.05) compared with the saline/unseeded mesh group, but differences disappeared by week 3.

Wound complications, including abscess formation and skin breakdown, differed among the 3 groups. Seroma and hematoma formation were not observed in any animal. Although there were no wound complications in the saline group, 100% of rats that were implanted with *E. coli*/unseeded mesh developed bilateral abscesses (8/8 rats; 16/16 meshes) and 50% of these animals (4/8 rats) developed skin breakdown. In contrast, only 1 rat (12.5%) in the *E. coli*/MSC-seeded group developed a unilateral abscess (1/8 animals; 1/16 meshes), and no animal in this group developed skin breakdown. Thus, abscess formation was markedly reduced in animals implanted with *E. coli*-inoculated MSC-seeded mesh compared with *E. coli*-inoculated unseeded mesh (p < 0.001). Seeding meshes with MSCs was also protective for skin breakdown, but this did not reach statistical significance (p = 0.08).

---

**Fig. 2.** Rat weights after implantation of MSC-seeded and MSC-unseeded Veritas Collagen Matrix. One week after surgery, animals implanted with *E. coli*-inoculated MSC-seeded mesh demonstrated improved weight gain relative to animals implanted with *E. coli*-inoculated unseeded mesh. Weight differences among groups disappeared by week 3. *p < 0.05, *E. coli*-inoculated unseeded mesh versus the other 2 groups; **p < 0.05, saline versus the 2 *E. coli* groups.
Macroscopic Findings

At necropsy, all unseeded meshes inoculated with saline demonstrated minimal incorporation into the surrounding host tissue and were easily removed with minimal adhesiolysis. In contrast, no mesh material was identified in any animal in the *E. coli*/unseeded mesh group (0/16 meshes; Figs. 3 and 4). The infections that developed at every implantation site in all animals in this group seemed to effect complete mesh degradation. In many cases, abscesses were still present at the time of harvest. Remarkably, 15 of 16 meshes (93.8%) in the *E. coli*/MSC-seeded mesh group were recovered intact (*p* < 0.001) with the lone exception occurring in the animal that developed a unilateral abscess. These MSC-seeded meshes demonstrated greater adherence to surrounding tissue compared with unseeded meshes inoculated with saline and required more extensive dissection to facilitate removal. Recovered meshes in the saline/unseeded group (*n* = 16) underwent a 49% ± 0.5% reduction in surface area, whereas recovered meshes in the *E. coli*/MSC-seeded group (*n* = 15) exhibited a 46±2% reduction (*p* = 0.19).

Microbiologic Findings

Quantitative cultures at 4 weeks revealed the presence of viable *E. coli* on 1 of 8 (12.5%) MSC-seeded meshes inoculated with *E. coli*, and this sample had a bacterial load of only 33 cfu per mesh. None of the saline/unseeded meshes were positive. Although no mesh material was recovered in the *E. coli*/unseeded mesh group, 2 samples of excised tissue at the site of implantation underwent microbiological testing and had bacterial loads of 2.2×10^7 and 2.7×10^7 cfu per sample. These results equate to 87.5% bacterial clearance in the MSC-seeded group versus 0% in the unseeded group (*p* = 0.001) in *E. coli*-inoculated animals. No rats had positive blood cultures.

Microscopic Findings

Representative images and histologic scores are presented in Figs. 5 and 6, respectively. Notably, scores could not be obtained for the *E. coli*/unseeded group because all implanted meshes in this group were completely degraded, which was confirmed on histologic examination (Fig. 5). At 4 weeks after implantation, saline/unseeded meshes and *E. coli*/MSC-seeded meshes were
well tolerated and exhibited minimal acute inflammation, with inflammatory cells consisting predominantly of mononuclear cells and few foreign body giant cells (Fig. 5). Cellular infiltration and tissue remodeling were generally limited to the periphery of implants. Statistically significant differences were not observed for any of the histological parameters between E. coli/MSC-seeded and saline/unseeded meshes (Fig. 6).

**DISCUSSION**

The ideal mesh material is one that enables optimal integration into host tissue, provides long-term structural integrity, and resists bacterial colonization; however, the search for the ideal mesh continues.² Although acellular bioprosthetic materials have been developed in an effort to improve biocompatibility and resistance to infection compared with synthetic meshes, experimental and clinical data suggest that in actuality, they may not resist infection or improve outcomes when used in contaminated surgical fields.³³,³⁸ Findings from this study revealed that the augmentation of a bioprosthetic (Veritas Collagen Matrix) with MSCs markedly improves bacterial clearance in vivo and enables preservation of mesh integrity when contaminated with E. coli.

Although it is possible that Veritas Collagen Matrix exhibits increased sensitivity to degradation in the setting of bacterial contamination, previous work from our laboratory and others have described similar findings in bioprosthetic materials ranging from acellular porcine dermis (Strattice, LifeCell Corp., Branchburg, N.J.)³⁵ to acellular human dermis (AlloDerm, LifeCell Corp.) and
shown to mediate antibacterial effects of MSCs.31,39,40 In addition, other antimicrobial proteins, such as Staphylococcus aureus β-defensin-2, lipocalin 2, and keratinocyte growth factor, also have been shown to mediate antibacterial effects of MSCs.31,39,40 In an animal model of sepsis, MSC administration enhanced bacterial clearance, in part, because of increased phagocytic activity of host immune cells.30 Thus, MSCs seem to have the ability to modulate the acute phase response while enhancing phagocytosis and upregulating expression of antimicrobial peptides. This is likely responsible for reducing the negative consequences of unchecked inflammation while directly enhancing pathogen clearance.37,50

Although the direct clinical relevance of this study may prompt speculation, taking cellular materials from bench to bedside is not an abstraction. Human viable wound matrices, such as Grafix (Osiris Therapeutics Inc., Columbia, Md.), which contains nonimmunogenic, cryopreserved MSCs, are already in use. This viable matrix shows promise in wound healing with particular emphasis on reducing rates of infection.41 Given the favorable characteristics of MSC-containing materials and the size/profitability of this market, one may envision clinical availability of a hybrid mesh (e.g., a viable wound matrix grafted to a biologic or synthetic substrate) or a preseeded cryopreserved mesh for reconstructive procedures in the not-too-distant future.

Limitations of this study exist. MSCs were not labeled before seeding meshes, and therefore, identification of MSCs was not attempted in tissues 4 weeks after implantation. In addition, this investigation did not quantify clinical outcomes other than infection and was restricted to a monomicrobial inoculum using a single bioprosthesis material. Preclinical studies examining the benefits of various MSC-seeded bioprosthetics for reconstructive procedures, such as abdominal wall repair in the setting of polymicrobial contamination, are warranted.

CONCLUSIONS

Augmenting a bioprosthetic mesh with MSCs seems to markedly enhance its resistance to infection, preserve mesh integrity, and facilitate incorporation into surrounding host tissue. Although others have demonstrated increased collagen deposition and neovascularization in seeded bioprosthetic materials, this study is the first to our knowledge revealing improved bacterial clearance in vivo.

REFERENCES

1. Baumann DP, Butler CE. Bioprosthetic mesh in abdominal wall reconstruction. *Semin Plast Surg*. 2012;26:18–24.
2. Burger JW, Luijendijk RW, Hop WC, et al. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. *Ann Surg*. 2004;240:578–583.
3. Breuing K, Butler CE, Ferzoco S, et al. Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. *Surgery* 2010;148:544–558.
4. Slater NJ, Knaapen L, Bokkerink WJ, et al. Large contaminated ventral hernia repair using component separation technique with synthetic mesh. *Plast Reconstr Surg*. 2015;136:796e–805e.
5. Geiser DJ, Reilly JC, Vaughan SG, et al. Safety and outcome of use of nonabsorbable mesh for repair of fascial defects in the presence of open bowel. *Dis Colon Rectum* 2003;46:1118–1123.

6. Souza JM, Dumanian GA. Routine use of bioprosthetic mesh is not necessary: a retrospective review of 100 consecutive cases of intra-abdominal midweight polypropylene mesh for ventral hernia repair. *Surgery* 2013;153:393–399.

7. Ditzel M, Deerenberg EB, Grotenhuis N, et al. Biologic meshes are not superior to synthetic meshes in ventral hernia repair: an experimental study with long-term follow-up evaluation. *Surg Endosc*. 2013;27:3654–3662.

8. Carbonell AM, Criss CN, Cobb WS, et al. Outcomes of synthetic mesh in contaminated ventral hernia repairs. *J Am Coll Surg*. 2013;217:991–998.

9. Patel KM, Bhano P. Complications of acellular dermal matrices in abdominal wall reconstruction. *Plast Reconstr Surg*. 2012;130(5 Suppl 2):216S–224S.

10. Darehzereshki A, Goldfarb M, Zehetner J, et al. Biologic versus nonbiologic mesh in ventral hernia repair: a systematic review and meta-analysis. *World J Surg*. 2014;38:40–50.

11. Slater NJ, van der Kolk M, Hendriks T, et al. Biologic grafts for ventral hernia repair: a systematic review. *Am J Surg*. 2013;205:220–230.

12. Rosen MJ, Kpata DM, Ermlich B, et al. A 5-year clinical experience with single-staged repairs of infected and contaminated abdominal wall defects utilizing biologic mesh. *Ann Surg*. 2013;257:991–996.

13. Flum DR, Horvath K, Koepsell T. Have outcomes of incisional hernia repair improved with time? A population-based analysis. *Ann Surg* 2003;237:129–135.

14. Millennium Research Group. *US Markets For Soft Tissue Repair*. Toronto, ON: Millennium Research Group, Inc; 2008.

15. Bhangu A, Fitzgerald JE, Singh P, et al. Systematic review and meta-analysis of prophylactic mesh placement for prevention of incisional hernia following midline laparotomy. *Hernia* 2013;17:445–455.

16. García-Ureña MA, López-Monchis J, Hernando LA, et al. Randomized controlled trial of the use of a large-pore polypropylene mesh to prevent incisional hernia in colorectal surgery. *Ann Surg* 2015;261:876–881.

17. Carlson TL, Lee KW, Pierce LM. Effect of cross-linked and non-crosslinked acellular dermal matrices on the expression of mediators involved in wound healing and matrix remodeling. *Plast Reconstr Surg*. 2013;131:697–705.

18. Asarias JR, Nguyen PT, Mings JR, et al. Influence of mesh materials on the expression of mediators involved in wound healing. *J Invest Surg*. 2011;24:87–98.

19. Nguyen PT, Asarias JR, Pierce LM. Influence of a new monofilament polyester mesh on inflammation and matrix remodeling. *J Invest Surg*. 2012;25:330–339.

20. Pierce LM, Asarias JR, Nguyen PT, et al. Inflammatory cytokine and matrix metalloproteinase expression induced by collagen-coated and uncoated polypropylene meshes in a rat model. *Am J Obstet Gynecol*. 2011;205:82.e1–82.e9.

21. Altman AM, Abdul Khalek FJ, Alt EU, et al. Adipose tissue-derived stem cells enhance bioprosthetic mesh repair of ventral hernias. *Plast Reconstr Surg*. 2010;126:845–854.

22. Zhao Y, Zhang Z, Wang J, et al. Abdominal hernia repair with a decellularized dermal scaffold seeded with autologous bone marrow-derived mesenchymal stem cells. *Acta Orthop* 2012;83:247–255.

23. Spelzini F, Manodoro S, Frigerio M, et al. Stem cell augmented mesh materials: an in vitro and in vivo study. *Int Urogynecol J*. 2015;26:675–683.

24. Nowicki M, Jundizil A, Nazarewski L, et al. Blood vessel matrix seeded with cells: a better alternative for abdominal wall reconstruction—a long-term study. *Biomed Res Int*. 2015;2015:890613.

25. Klinger A, Kawata M, Villalobos M, et al. Living scaffolds: surgical repair using scaffolds seeded with human adipose-derived stem cells. *Hernia* 2016;20:161–170.

26. Iyanki TS, Dunne IW, Zhang Q, et al. Adipose-derived stem-cell-seeded non-cross-linked porcine acellular dermal matrix increases cellular infiltration, vascular infiltration, and mechanical strength of ventral hernia repairs. *Tissue Eng Part A* 2015;21:475–485.

27. Chen L, Tredget EE, Wu PY, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. *PLoS One* 2008;3:e1886.

28. Mezey E, Nemeth K. Mesenchymal stem cells and infectious diseases: smarter than drugs. *Immunol Lett*. 2015;168:208–214.

29. Yuan Y, Lin S, Guo N, et al. Marrow mesenchymal stromal cells reduce methicillin-resistant *Staphylococcus aureus* infection in rat models. *Cytotherapy* 2014;16:56–63.

30. Mei SH, Haitsma JJ, Dos Santos CG, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. *Am J Respir Crit Care Med*. 2010;182:1047–1057.

31. Sung DK, Chang VS, Sung SI, et al. Antibacterial effect of mesenchymal stem cells against *Escherichia coli* is mediated by secretion of beta-defensin-2 via toll-like receptor 4 signalling. *Cell Microbiol*. 2016;18:424–436.

32. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 2010;28:2229–2238.

33. Cole WC, Balent EM, Masella PC, et al. An experimental comparison of the effects of bacterial colonization on biologic and synthetic meshes. *Hernia* 2015;19:197–205.

34. Bellows CF, Wheatley BM, Moroz K, et al. The effect of bacterial infection on the biomechanical properties of biological mesh in a rat model. *PLoS One* 2011;6:e21228.

35. Bellows CF, Wheatley B, Moroz K, et al. Histologic evaluation of biologic meshes following colonization with *Pseudomonas aeruginosa*. *J Surg Res*. 2012;175:e35–e42.

36. Limpert JN, Desai AR, Kumpf AL, et al. Repair of abdominal wall defects with bovine pericardium. *Am J Surg*. 2009;198:e60–e65.

37. Jenkins ED, Melman L, Deeken CR, et al. Evaluation of fenestrated and non-fenestrated biologic grafts in a porcine model of mature ventral incisional hernia repair. *Hernia* 2010;14:599–610.

38. Lee L, Mata J, Landry T, et al. A systematic review of synthetic and biologic materials for abdominal wall reinforcement in contaminated fields. *Surg Endosc*. 2014;28:2531–2546.

39. Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. *Thorax* 2012;67:533–539.

40. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. *Am J Respir Crit Care Med*. 2013;187:751–760.

41. Lavery LA, Palmer J, Shebetka KA, et al. Grafix Diabetic Foot Ulcer Study Group. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J*. 2014;11:554–560.